GlassScriptPhysician profile
Richard Joo
NPI 1851351282
$1,847.28
in general payments reported to CMS, 2019-2025
22 companies · $520 in 2025
The $520 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $64.60 · 2021: $192 · 2022: $303 · 2023: $307 · 2024: $257 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $542.03 | 2019-2025 | Evenity, Krystexxa, Otezla |
| Novo Nordisk INC | $303.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $200.56 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.19 | 2019-2023 | Jardiance, Tradjenta |
| Abbvie INC. | $91.55 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $75.60 | 2022-2024 | Farxiga |
| Ibsa Pharma INC. | $75.22 | 2022-2025 | Tirosint, Licart, Flector |
| Nestle Healthcare Nutrition INC. | $70.93 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.28 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $47.92 | 2019-2024 | Ztlido |
| Otsuka America Pharmaceutical, INC. | $37.60 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $31.92 | 2023 | |
| Azurity Pharmaceuticals, INC. | $31.72 | 2023-2024 | Edarbi, Horizant |
| Almatica Pharma LLC | $26.62 | 2021 | |
| Amarin Pharma, INC. | $26.57 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $20.90 | 2025 | Purified Cortrophin Gel |
| Aimmune Therapeutics, INC. | $16.24 | 2024 | |
| Averitas Pharma INC. | $15.79 | 2025 | Qutenza |
| Janssen Pharmaceuticals, INC | $14.10 | 2019 | |
| Vivus LLC | $13.80 | 2024 | Pancreaze |
| Gilead Sciences, INC. | $13.12 | 2019 | |
| Allergan, INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Joo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.